News About: Pharm. Industry
Will GSK escape from misfortune in its vaccine business?GSK, which used be called the strong but has had difficulties in vaccine, is planning to announce its ambitious work after a long time.
The GSK’s ambitious work is the shingles...
|
The size of the domestic CRO market is KRW 280 billion, leading growth of the foreign market
It is observed that the domestic CRO (Contract Research Organization) industry has been expanded by the rise of new clinical trials. The total sales of the CRO industry exceeded KRW 280 billion last year.
On the 27th...
The tired pharmaceutical industry has started with the research for ‘pharmaceutical distribution margins’
A survey will be conducted on the actual condition of pharmaceutical distribution margins. This is a survey conducted not by the Korea Pharmaceutical Distribution Association and the distribution industry, but the Kor...
Co-promotion played the key role in sale growth of large pharmaceutical companies in the first quarter
It is observed that external growth of large pharmaceutical companies was impacted by co-promoted products in the first quarter.
As co-promotion products of multinational pharmaceutical companies are grown to their m...
Exports of the 1/4 quarter pharmaceutical industry increased 29% up
Exports of the pharmaceutical industry on the first quarter of 2015 increased 29% up compared to the last year.
The Korea Health Industry Development Institute unveiled through indexes of major healthcare industries ...
On the first quarter, top sales pharmaceutical companies are staring slowly while middle and low companies are making advancements
The top pharmaceutical companies have been begun poorly in performance.
Among the top sale companies, called ‘Big 5,’ 4 of them have showed decreased profitability compared to the same quarter of the last year, excep...
Will GSK recover reputation through its ambitious products?GSK, which has been frozen in performance, a company specializing in vaccines, has taken the first step for its revival.
The company recorded low performance in its ambitious p...
|
The counterattack of BSM aims Samjin, United, JW and IldongKeeping the top position in prescriptions, Baraclude (BMS) has started to counterattack.
According to the industry concerned, Bristol-Myers Squibb Holdings Island owning the pe...
|
Bayer Korea has a high chance to take over ‘Mercilon’As Bayer Korea disposed its 4 oral contraceptives to Dong-A Pharmaceutical by sale, it now has a higher chance to take over ‘Mercilon.’
Since Dong-A Pharmaceutical took over th...
|
The Green Cross’s ‘Shinbaro’ has been approved for its safety and effectiveness in its Phase 4 clinical trialGreen Cross (President Eun-chul Huh) announced on the 7th that it unveiled the Pharse 4 clinical trial result of the arthritis treatment ‘Shinbaro Cap’ in its poster session at ...
|
